Unknown

Dataset Information

COPD patient satisfaction with ipratropium bromide/albuterol delivered via Respimat: a randomized, controlled study.


ABSTRACT:

Background

Ipratropium bromide/albuterol Respimat inhaler (CVT-R) was developed as an environmentally friendly alternative to ipratropium bromide/albuterol metered-dose inhaler (CVT-MDI), which uses a chlorofluorocarbon propellant.

Objective

The objective of this study was to evaluate patient satisfaction, device usage, and long-term safety of CVT-R compared to CVT-MDI, and to the simultaneous administration of ipratropium bromide hydrofluoroalkane (HFA; I) and albuterol HFA (A) metered-dose inhalers as dual monotherapies (I + A).

Design

This is a 48-week, open-label, randomized, active-controlled, parallel-group study (n = 470) comparing CVT-R to CVT-MDI and to I + A.

Participants

Patients were at least 40 years of age, diagnosed with chronic obstructive pulmo

SUBMITTER: Ferguson GT 

PROVIDER: S-EPMC3607534 | biostudies-literature | 2013

REPOSITORIES: biostudies-literature